FORMULATIONS TRANSDERMIQUES POUR L'ADMINISTRATION DE COMPOSES DE BERBERINE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES ET DE PATHOLOGIES SENSIBLES A LA BERBERINE
The present application is directed to transdermal formulations for the delivery of berberine compounds to a subject for the treatment of berberine-responsive diseases. In particular, the transdermal formulation comprises: (a) an aqueous phase comprising water and at least one water soluble emulsion stabilizer； (b) an oil phase comprising at least one emulsifier, at least one oil soluble emulsion stabilizer, at least one emollient comprising at least one flavonoid and at least one other emollient； wherein the oil and aqueous phases form an emulsion； (c) an external phase comprising at least one flavonoid containing-extract, at least one phospholipid-complexed flavonoid and at least one source of berberine or analog or derivative thereof； and optionally (d) at least one preservative phase.
